You are not logged in

New York Magazine

Skip to content, or skip to search.

Skip to content, or skip to search.

ARCHIVES

James J. Cramer

September 22, 2003 | The Bottom Line
Clockers

A mutual-fund giant let Canary Capital turn back time to create a no-risk, all-profit paradise. Next up for the perps: the all-risk, no-profit world known as jail.

May 7, 2001 | The Bottom Line
Look Who's Back

Ready for a shock? Not only is the economy going to rebound, but some of the best stock buys right now can be found in the much-despised tech sector.

May 2, 2005 | The Bottom Line
No Bear There

The market’s recent nosedive was allegedly caused by four factors. The thing is, none of them really matters.

September 13, 2004 | The Bottom Line
Campaign Finance

Which presidential candidate is more apt to boost the fortunes of your portfolio? Before you answer “W.,” do the math.

June 25, 2001 | The Bottom Line
Long-Distance Runner

You'll never guess who dull old Verizon has been humiliating in the brutal telecommunications race. (No names, please, but the poor fool's initials are AT&T.)

April 8, 2002 | The Bottom Line
Account Me Out

The Arthur Andersen accounting scandal offers the government a once-in-a-lifetime opportunity to fix a system rife with corruption and double-dealing -- but will it use it?

November 11, 2002 | The Bottom Line
Dot-Comeback

Nobody can quite believe it, but there are four legitimate -- and deserving -- Netco's that are reviving the lost promise of the New Economy. And their stocks are bargains (seriously).

August 28, 2000 | The Bottom Line
Survivor!

When the merger with Time Warner was announced, we all thought high-flying AOL was getting shafted; now it looks like the smartest move a dot-com ever made.

October 6, 2003 | The Bottom Line
Delisted

C’mon—all NYSE chief Dick Grasso did was negotiate one hell of a pay package. His downfall has a lot more to do with how the money changed him.

November 1, 2004 | The Bottom Line
Outlook Murky

The Vioxx scandal is more than a headache for the long-beloved drug giant. It could be the death of the company as we know it.

Advertising
Current Issue
Subscribe to New York
Subscribe

Give a Gift